The ␥-aminobutyric acid A (GABA) receptor in the mammalian central nervous system is composed of pentameric combinations of ␣1-6, ␤1-4, ␥1-3, ␦1, and/or ⑀1 subunit subtypes. Although each of the different subunits influences the functional properties of ␥-aminobutyric acid A receptors (GABARs), the ␣ subunit subtypes have been shown to be important for activation of the receptor by GABA and pentobarbital and the regulation of GABARs by numerous allosteric regulators, including benzodiazepines, furosemide, zinc, and lanthanum. However, with the exception of the benzodiazepines, the ␣ subtype domain that is responsible for the action of these allosteric compounds is unknown. The ␣1 and ␣6 subtypes are among the most diverse of the ␣ subunit family and confer a different responsiveness of GABARs to GABA and many of the allosteric modulators. These regulatory compounds act after extracellular application and therefore likely act on extracellular GABAR sites, the largest of which is the amino-terminal extracellular domain. To determine the role of this domain in the action of these allosteric regulatory agents, we constructed chimeras of the rat ␣1 and ␣6 subtypes with a splice site within the first putative transmembrane domain (TM). This separated the large extracellular amino-terminal domain from the transmembrane, intracellular, and TM2-3 and carboxyl-terminal extracellular domains of the subunit. The chimeric subtypes were expressed in L929 fibroblasts along with ␤3 and ␥2L subtypes, and their pharmacological properties were determined with whole-cell electrophysiological recording. The ␣ subtype amino-terminal extracellular domain was the primary determinant of GABA sensitivity and was responsible for the functional properties of activation by pentobarbital, sensitivity to diazepam, potentiation by lanthanum, and high affinity inhibition by furosemide. The remaining carboxyl-terminal domains influenced the GABA sensitivity and determined zinc sensitivity and low affinity inhibition by furosemide. Both domains were apparently required for inhibition by lanthanum.
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Fast inhibitory neurotransmission in the mammalian central nervous system is mediated principally through the GA-BAR. The GABAR is composed of a pentameric combination of ␣1-6, ␤1-4, ␥1-3, ␦1, and/or ⑀1 subunit subtypes that form an intrinsic chloride ion channel. GABAR subunits are thought to have a membrane topology similar to that of nicotinic acetylcholine receptor subunits, with a large extracellular amino-terminal domain, four TMs (TM1-4), a small extracellular domain between TM2 and TM3, and a large cytoplasmic domain between TM3 and TM4 (Fig. 1A) . The activity of GABARs is modulated through a large number of allosteric regulatory sites. The properties of these allosteric sites are influenced by the subunit subtype composition of the GABAR (see review in Ref. 1) . The identity of the ␣ subtype affects the receptor responsiveness to GABA and pentobarbital and to many allosteric agents, including benzodiazepines, divalent and trivalent cations, and furosemide.
The ␣1 and ␣6 subtypes are among the most divergent of the ␣ family subtypes in their functional properties, and they share the least structural homology of the family members (59% amino acid identity) (2, 3) . The differences in the amino acid sequences between ␣1 and ␣6 subtypes occur primarily in the large extracellular amino-terminal domain and the intracellular loop between TM3 and TM4, whereas the TMs and the TM2-3 extracellular domain are well conserved (83% amino acid identity). Receptors containing the ␣6 subtype along with ␤ and ␥2 subtypes are more sensitive to GABA and to direct activation by pentobarbital than are receptors containing the ␣1 subtype. Receptors containing the ␣1 subtype along with ␤ and ␥2 subtypes are potentiated by benzodiazepine agonists and lanthanum but are relatively insensitive to inhibition by zinc and furosemide. In contrast, receptors containing the ␣6 subtype along with ␤ and ␥2 This work was supported by National Institutes of Health Grant RO1-NS33300 (R.L.M.) and National Institute on Drug Abuse Grant 5T32-DA07268 (J.L. F.) subtypes are insensitive to benzodiazepines, more sensitive to inhibition by zinc, and strongly inhibited by lanthanum and furosemide (2, 4 -7) . The structural bases for the differences in allosteric regulation of the ␣1 and ␣6 subtypes are not known except for the benzodiazepines. Potentiation by benzodiazepine agonists requires a histidine residue in the large amino-terminal extracellular domain (H101 in rat ␣1); the benzodiazepine-insensitive ␣4 and ␣6 subtypes contain an arginine residue at the equivalent location (8) . Other residues in this domain have also been shown to contribute to the functional properties of several benzodiazepine ligands (9) . No studies on the zinc site have been reported for the GABAR, although a histidine residue located in the extracellular amino-terminal domain is required for zinc inhibition of the structurally related 1 subtype of GABA C receptors (10) . Although structural domains important for direct activation by pentobarbital have not been localized, it has been shown that pentobarbital acts through different sites than does GABA (11) . No information is available on the sites of action of lanthanum or furosemide on GABARs. All these agents act after application to the extracellular surface of the receptor and therefore likely bind to extracellular sites or the poreforming TM. The amino-terminal domain is the largest extracellular domain, and the ␣1 and ␣6 subtypes share relatively low sequence homology in this region. Therefore, structural differences in the amino-terminal extracellular domain may be predominantly responsible for the differences in responsiveness of GABARs containing ␣1 and ␣6 subtypes to these regulatory agents.
To determine the role of the large extracellular aminoterminal domain in the functional properties of these GABAR regulatory sites, we created chimeric constructs of the rat ␣1 and ␣6 subtypes by interchanging their amino-terminal extracellular domains (Fig. 1) . The chimeric subtypes contained the large extracellular domain and approximately one half of the TM1 of one of the ␣ subtypes, with the remainder of the subunit structure from the other subtype, including TM2-4, the extracellular bridge between TM2 and TM3, and the large intracellular loop between TM3 and TM4. To generate the splice site, a restriction site for DraIII was created in the ␣1 subtype cDNA, converting a leucine residue to the threonine residue (L258T) present at this location in the ␣6 subtype (Fig. 1B) . This mutation did not affect any of the functional properties of the ␣1 subtype examined in this study. Plasmids containing these constructs were transfected along with ␤3 and ␥2L subtypes into L929 fibroblasts, and the responsiveness of the GABARs to GABA, pentobarbital, diazepam, furosemide, zinc, and lanthanum was measured with whole-cell recording. The structural differences between the ␣1 and ␣6 subtypes could cause functional differences in the response to these modulators through a large number of mechanisms, including changes in binding or transduction properties. Because we examined the functional responses to these agents, not their binding properties, we could not distinguish among these mechanisms.
Materials and Methods
Construction of mutant and chimeric ␣ subtype cDNAs. Full-length cDNAs for the rat GABAR ␣1 (Dr. A. Tobin, University of California, Los Angeles) and ␣6 (F. Tan, University of Michigan) subtypes were subcloned into the pBluescript II KS (Ϫ) vector. To create a restriction site for DraIII in the ␣1 subtype, primers were created to make six nucleotide substitutions, converting the sequence TCTGCCATGCAT to CACTCCGTGCAC. This resulted in the change of a single amino acid, Leu258 to Thr258. A region between restriction sites for BsmI and NsiI containing the sequences to be modified was amplified using polymerase chain reaction techniques with a 5Ј primer of 5Ј-GGATGAAAGATTAAAATTCAAAGGGAC-CCATGAC-3Ј and a 3Ј primer of 3Ј-GCCGATGAAACAATAAAGTT-TGTATGTGAGGCACGTG-5Ј, which amplified the sequence from nucleotide 290 to nucleotide 783 of the open reading frame sequence of the ␣1 subtype. Oligonucleotide primers were synthesized at the University of Michigan DNA synthesis core facility. This region was spliced out of the wild-type sequence through digestion with BsmI and NsiI. The amplified fragment was digested with BsmI and AspHI, gel-purified, and ligated into the wild-type cDNA. Introduction of the mutation into the ␣1 sequence was verified with restriction mapping using NsiI and DraIII enzymes. To form the chimeras, both the mutant ␣1 and wild-type ␣6 subtype cDNAs were digested with DraIII, releasing a portion of the vector and the amino-terminal region of the subtype to the restriction site within TM1. The result- Fig. 1 . Location of the chimera splice site. A, GABAR subunit. The structure of GABAR subunits consists of four TMs (TM1-4), a large amino-terminal extracellular domain, and a large intracellular domain between TM3 and TM4. Arrow, splice site for the chimeras was located within TM1 (not drawn to scale). B, Comparison of the amino acid sequence of TM1 of wild-type, mutant, and chimera subtypes. The full sequence of the rat ␣1 subtype is shown. Only differing residues and residues surrounding the splice site are shown for the other subtypes. Dashes, residues identical to the wild-type ␣1 subtype. Bold, leucine residue changed to a threonine residue in the mutant ␣1 subtype. Solid line, location of the splice site between the proline and cysteine residues. ing fragments were gel-purified, swapped, and re-ligated to the other subtype to form the chimeric sequences. The ␣1/␣6 chimera and the ␣1 (L258T) subtype cDNAs were released from their vectors using HindIII and PstI. The ␣6/␣1 chimera was released using SpeI and XhoI. T4 DNA polymerase was used to fill in the ends. A BglII linker was then ligated to the ends, and the cDNAs were digested with BglII to allow ligation into the pCMVNeo vector using the BglII site. The sequence of the inserted PCR fragment was verified for all constructs with DNA sequencing.
Transfection of L929 cells. Full-length cDNAs for the rat GABAR ␣1 (Dr. A. Tobin), ␤3 (Dr. D. Pritchett, University of Pennsylvania), and ␣6 and ␥2L (F. Tan) subtypes were subcloned into the pCMVNeo expression vector (12) and transfected into the mouse fibroblast cell line L929 (American Type Culture Collection, Rockville, MD). Chimeric constructs and the ␣1 (L258T) mutant subtype were prepared as described above. For selection of transfected cells, the plasmid pHook-1 (InVitrogen, San Diego, CA) containing cDNA encoding the surface antibody sFv was also transfected into the cells. L929 cells were maintained in Dulbecco's modified Eagle's medium plus 10% heat-inactivated horse serum, 100 IU/ml penicillin, and 100 g/ml streptomycin. Cells were passaged by a 5-min incubation with 0.5% trypsin/0.2% EDTA solution in phosphate-buffered saline (10 mM Na 2 HPO 4 , 150 mM NaCl, pH 7.3).
The cells were transfected using a modified calcium phosphate method (13, 14) . Plasmids encoding GABAR subtype cDNAs were added to the cells in 1:1 ratios of 4 g each plus 8 g of the plasmid encoding sFv. After a 4-6-hr incubation at 3% CO 2 , the cells were treated with a 15% glycerol solution in BBS buffer (50 mM BES, 280 mM NaCl, 1.5 mM Na 2 HPO 4 ) for 30 sec. The selection procedure for sFv antibody expression was performed 20-28 hr later as described by Greenfield et al. (15) . Briefly, the cells were passaged and mixed with 5 l of magnetic beads coated with hapten (ϳ7.5 ϫ 10 5 beads) (InVitrogen). After 30-60 min of incubation to allow the beads to bind to positively transfected cells, the beads and bead-coated cells were isolated using a magnetic stand. The selected cells were resuspended into Dulbecco's modified Eagle's medium, plated onto 35-mm culture dishes, and used for recording 18-28 hr later.
Electrophysiological recording solutions and techniques. For whole-cell recording, the external solution consisted of 142 mM NaCl, 8.1 mM KCl, 6 mM MgCl 2 , 1 mM CaCl 2 , 10 mM glucose and 10 mM HEPES, pH 7.4, and osmolarity adjusted to 295-305 mOsM. Recording electrodes were filled with an internal solution of 153 mM KCl, 1 mM MgCl 2 , 5 mM K-EGTA, 10 mM HEPES, and 2 mM MgATP, pH 7.4, and osmolarity adjusted to 295-305 mOsM. These solutions provided a chloride equilibrium potential near 0 mV. Patch pipettes were pulled from thick-walled borosilicate glass with an internal filament (World Precision Instruments, Pittsburgh, PA) on a P-87 Flaming Brown puller (Sutter Instrument Co., San Rafael, CA) and fire-polished to a resistance of 5-10 M⍀. Drugs were applied to cells using a "multipuffer" system with a 10-90% rise time of 70-150 msec (16) . Currents were recorded with a List EPC-7 (List Electronics, Darmstadt, Germany) patch-clamp amplifier and stored on ␤ videotape (Sony). All experiments were performed at room temperature.
Analysis of whole-cell currents. Whole-cell currents were analyzed off-line using the programs Axotape (Axon Instruments, Foster City CA) and Prism (GraphPAD Software, San Diego, CA). Normalized concentration-response data for the different isoforms were fit with a four-parameter logistic equation: current ϭ maximum current/{1 ϩ (10 (logEC 50 Ϫ log[drug])*n)}, where n represents the Hill coefficient. All fits were made to normalized data with the current expressed as a percentage of the maximum current elicited by saturating GABA concentrations for each cell or, in the case of modulators, a percent of the response to GABA alone. Statistical tests were performed using the Instat program (GraphPAD). Comparisons of the receptor properties were performed with one-way analysis of variance and Tukey-Kramer multiple comparisons test with a statistical significance level of 0.05.
Results
Responsiveness to GABA. All ␣ subtype constructs in combination with ␤3 and ␥2L subtypes produced GABAsensitive currents in L929 fibroblasts ( Fig. 2A ). Cells were voltage-clamped at Ϫ50 mV, and whole-cell currents were recorded in response to varying concentrations of GABA. The amplitudes of the maximum currents evoked by GABA were similar for all GABAR isoforms, with average Ϯ standard error values of 974.6 Ϯ 154.7 pA (␣1␤3␥2L, 13 cells), 1293.9 Ϯ 235.9 pA (␣1 (L258T) ␤3␥2L, seven cells), 812.0 Ϯ 179.0 pA (␣6␤3␥2L, nine cells), 1123.6 Ϯ 354.3 pA (␣1/ ␣6␤3␥2L, nine cells), and 782.0 Ϯ 226.0 pA (␣6/␣1␤3␥2L, seven cells). The maximum currents were not significantly different among isoforms. The GABAR isoforms exhibited different GABA sensitivities (Fig. 2B) . The ␣1␤3␥2L isoform was ϳ7-fold less sensitive to GABA (average EC 50 ϭ 12.1 Ϯ 2.5 M, seven cells) than the ␣6␤3␥2L isoform (average EC 50 ϭ 1.8 Ϯ 0.2 M, six cells). The ␣1 (L258T) ␤3␥2L receptor had the same sensitivity to GABA as the wild-type ␣1␤3␥2L receptor, with an average GABA EC 50 value of 12.1 Ϯ 1.7 M (four cells). Receptors containing the ␣1/␣6 chimera were ϳ6-fold less sensitive to GABA than the ␣1␤3␥2L receptor, with an average GABA EC 50 value of 69.2 Ϯ 6.4 M (five cells). In contrast, receptors containing the ␣6/␣1 chimera were ϳ5-fold more sensitive to GABA than the ␣6␤3␥2L receptor, with an average EC 50 value of 0.34 Ϯ 0.055 M (six cells). The logEC 50 values for GABA were significantly different among all isoforms except for receptors containing the ␣1(L58T) mutation or the wild-type ␣1, which were not different from each other.
Responsiveness to pentobarbital. Pentobarbital can directly activate GABARs with an efficacy dependent on the subunit subtype composition (7). The ␣1-containing receptors are less responsive to pentobarbital than are ␣6-containing receptors. Pentobarbital is more effective as an agonist than GABA at ␣6␤3␥2L receptors, producing larger maximum currents than GABA. The structural dependence of pentobarbital activation is different from that of GABA because mutations in the ␤ subunit that prevent activation by GABA do not affect pentobarbital activity (11) . In addition, activation by pentobarbital is not prevented by bicuculline, a competitive antagonist at the GABA site, although currents are blocked by the noncompetitive antagonist picrotoxin (7). The ␣6␤3␥2L isoform was highly sensitive to pentobarbital, with an EC 50 value of 44 M and an average maximum current evoked by 300 M pentobarbital that is 218.5 Ϯ 58.7% (six cells) of that evoked by 600 M GABA (Fig. 3) . In contrast, receptors containing the ␣1 and ␣1 (L258T) subunits were nearly equally activated by 300 M pentobarbital or 600 M GABA, with average currents in response to 300 M pentobarbital that were 85.2 Ϯ 7.9% (six cells, ␣1␤3␥2L) and 88.2 Ϯ 8.0% (five cells, ␣1 (L258T) ␤3␥2L) of the response to GABA. EC 50 values for pentobarbital were 101 M (␣1␤3␥2L) and 126 M (␣1 (L258T) ␤3␥2L). The amino-terminal extracellular domain seemed to be principally responsible for the differential effect of pentobarbital. The ␣1/␣6␤3␥2L isoform was ␣1-like in its response to pentobarbital, with 300 M pentobarbital evoking currents 95.0 Ϯ 3.3% (five cells) of the current response to 600 M GABA with an EC 50 value of 131 M. The efficacy of pentobarbital was not significantly different among the ␣1-, ␣1 (L258T) -and ␣1/␣6-containing receptors. 
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The ␣6/␣1␤3␥2L isoform was ␣6-like, with 300 M pentobarbital approximately twice as effective as 600 M GABA (196.3 Ϯ 15.0%, four cells) and an EC 50 value of 35 M. The efficacy of pentobarbital at the ␣6/␣1␤3␥2L isoform was not significantly different from the response of the ␣6␤3␥2L isoform.
Responsiveness to diazepam. A histidine residue in the amino-terminal extracellular domain of the ␣1 subtype (H101 in rat ␣1) is required for sensitivity to the benzodiazepine agonist diazepam (8) . The ␣6 subtype contains an arginine residue in this location, which accounts for its insensitivity to benzodiazepine agonists. Consistent with these reports, the ␣1␤3␥2L, ␣1 (L258T) ␤3␥2L, and ␣1/␣6␤3␥2L receptor currents were all equally sensitive to potentiation by diazepam, with EC 50 values of 38 nM (␣1␤3␥2L, four cells), 38 nM (␣1 (L258T) ␤3␥2L, three cells), and 42 nM (␣1/␣6␤3␥2L, three cells), whereas the ␣6␤3␥2L (three cells) and ␣6/␣1␤3␥2L (four cells) receptor isoform currents were insensitive to diazepam (Fig. 4) . The logEC 50 values for diazepam and the degree of current potentiation by 800 nM diazepam were not significantly different for the sensitive isoforms. The effects of 2 M diazepam were not significantly different for the insensitive ␣6␤3␥2L and ␣6/␣1␤3␥2L isoforms.
Responsiveness to furosemide. Furosemide, a loop diuretic, is also a specific inhibitor of GABARs containing ␣4 or ␣6 subtypes (4, 17) . Furosemide is much less effective at receptors containing an ␣1 subtype. ␣␤3␥2L receptors containing wild-type ␣1 or the ␣1 (L258T) mutant showed a low sensitivity to furosemide, with average inhibition by 3 mM furosemide to 51 Ϯ 3.6% (␣1␤3␥2L, five cells), and 58 Ϯ 4.3% (Fig. 5) . The degree of current inhibition by 3 mM furosemide of the mutant and wild-type ␣1 subtypes was not significantly different. Due to the poor solubility of furosemide in water, complete concentration-response relationships could not be determined for these isoforms. The ␣6␤3␥2L current was highly sensitive to inhibition by furosemide, with an IC 50 value of 27 M and nearly complete inhibition of the current (six cells). The appearance of the currents during inhibition by furosemide also differed (Fig.  5A) . For ␣6␤3␥2L currents, higher concentrations of furosemide (Ն30 M) caused an increase in the apparent rate of desensitization, with the peak current declining rapidly. In contrast, for ␣1␤3␥2L currents, furosemide caused a uniform decrease in the whole-cell current, with no apparent difference between peak and steady state current.
The ␣1/␣6␤3␥L current had an intermediate sensitivity to inhibition by furosemide compared with the ␣1-and ␣6-subtype-containing receptors, with an IC 50 value of 180 M (five cells). The peak currents were less affected by furosemide than the steady state currents, causing an increase in the apparent desensitization of the current (Fig. 5) . The ␣6/␣1 chimera conferred high sensitivity to current inhibition by furosemide, with an EC 50 value of 35 M (five cells), similar to that for the ␣6␤3␥2L isoform. The furosemide logEC 50 value for ␣1/␣6␤3␥2L currents was significantly different from that for ␣6␤3␥2L and ␣6/␣1␤3␥2L currents, which were not significantly different from each other. The degree of inhibition by 3 mM furosemide of ␣1/␣6␤3␥2L current was significantly greater than that for both ␣1 and ␣1 (L258T) subtype-containing currents. Interestingly, the shape of the inhibited ␣6/␣1␤3␥2L currents was more like that of the inhibited ␣1␤3␥2L currents, with no appearance of increased desensitization, even at concentrations of furosemide that produced nearly complete inhibition of the current (Fig. 5A) . For almost all cells, high concentrations of furosemide seemed to slow the rate of return of the currents to base-line after removal of GABA.
Inhibition by zinc. The divalent cation zinc inhibits GA-BAR currents in a subunit subtype-dependent manner. Both ␣␤ and ␣␤␦ currents are highly sensitive to zinc inhibition, with IC 50 values of Ͻ5 M (5, 18) . The addition of a ␥ subunit decreases the sensitivity to zinc by ϳ10-100-fold. However, the ␣ subtype also influences the zinc sensitivity; receptors B, Concentration-response relationships were constructed by expressing the peak current in response to pentobarbital as a percentage of the response to 600 M GABA for each cell. Symbols and bars, mean Ϯ standard error. Data were fit with a four-parameter logistic equation. with ␣5 and ␣6 subtypes, even in combination with the ␥2L subtype, are more sensitive to current inhibition by zinc than are ␣1 subtype-containing receptors (5, 19) .
The ␣1␤3␥2L and ␣1 (L258T) ␤3␥2L currents were inhibited by zinc with IC 50 values of 111 M (four cells) and 153 M (five cells), respectively (Fig. 6) . The ␣6␤3␥2L isoform, however, was Ͼ4-fold more sensitive to inhibition by zinc, with an IC 50 value of 27 M (five cells). For all these isoforms, inhibition of the current was incomplete, with ϳ20% of the current remaining with 1 mM zinc.
The ␣1/␣6␤3␥2L isoform was ␣6 subtype-like in its sensitivity to zinc inhibition, with an IC 50 value of 26 M (four cells). However, the residual, unblocked current with 1 mM zinc was slightly less for the chimera, with ϳ13% of the current remaining (Fig. 6B) . The ␣6/␣1␤3␥2L isoform was ␣1 subtype-like, with an IC 50 value of 126 M (five cells).
The logEC 50 values for zinc inhibition were not significantly different among the ␣1␤3␥2L, ␣1 (L258T) ␤3␥2L, and ␣6/␣1␤3␥2L isoforms. The logEC 50 values of the ␣6␤3␥2L and ␣1/␣6␤3␥2L isoforms were not different from one another, whereas both were significantly different from the less-sensitive isoforms. The degree of inhibition by 1 mM zinc was not significantly different among the isoforms.
Effect of lanthanum.
The trivalent cation lanthanum affects GABAR currents in an ␣ subunit subtype-dependent manner (6) . ␣1␤3␥2L currents are potentiated by lanthanum, whereas ␣6␤3␥2L and ␣6␤3␦ currents are inhibited. The currents from the ␣1␤3␥2L and ␣1 (L258T) ␤3␥2L isoforms were potentiated by lanthanum ϳ2-fold, with EC 50 values of 233 M (␣1␤3␥2L, four cells) and 263 M (␣1 (L258T) ␤3␥2L, five cells) (Fig. 7) . The logEC 50 value and degree of potentiation by lanthanum for these isoforms were not significantly different. The ␣6␤3␥2L isoform was inhibited by lanthanum with an IC 50 value of 193 M (five cells) and a maximal inhibition to ϳ40% of the control current.
The ␣1/␣6␤3␥2L currents were potentiated by lanthanum, with an EC 50 value (190 M, five cells) and maximum potentiation (209%) similar to those of the ␣1 subtype-containing receptors. The logEC 50 value and degree of potentiation by lanthanum were not significantly different from that of the ␣1 and ␣1 (L258T) subtype-containing receptors. The ␣6/␣1␤3␥2L isoform showed an intermediate response to lanthanum, with very weak potentiation of the current by lanthanum (122.3 Ϯ 8.4% of control currents by 1 mM lanthanum, four cells). The effect of 1 mM lanthanum on the ␣6/ 
Discussion
To examine the contribution of the amino-terminal extracellular domain to the differential regulation of the ␣1 and ␣6 subtypes by several allosteric agents, we created chimeric subunits containing the entire amino-terminal extracellular domain and part of the first TM of one subtype spliced with the remaining subunit structure of the other subtype. This separated the largest extracellular portion of the subunit from the TMs. The carboxyl-terminal domains of the chimeras also included all the intracellular regions of the subtype in addition to a short extracellular sequence between TM2 and TM3. To form the chimeras, mutations were made in the ␣1 subtype sequence to create a restriction site; this resulted in the conversion of Leu258 to a threonine residue. This mutation had no effect on any of the pharmacological properties of the receptor examined in this study. The chimeric constructs efficiently expressed functional GABARs when cotransfected with ␤3 and ␥2L subtypes in L929 fibroblasts; this indicates that the chimeric ␣ subtypes assembled with ␤3 and ␥2L subtypes to form functional GABARs. We examined the responses to GABA, pentobarbital, diazepam, furosemide, zinc, and lanthanum to determine whether the amino-terminal domain and/or the remaining carboxyl-terminal domains were involved in the actions of these agents (Table  1 ). Structural differences in the subtypes could cause changes in the effect or effectiveness of the allosteric modulators through many different mechanisms. The structures could form part of the binding site or the signal transduction pathways or influence either of these through remote effects on secondary, tertiary, or quaternary structures of the receptor. We can conclude from these results only whether these structural domains contribute to the differences between the properties of the ␣1 and ␣6 subtypes. It is likely that other regions of the subtypes also contribute to the binding or transduction sites but are not responsible for the functional differences among the subtypes. A, Representative whole-cell traces from transfected L929 fibroblasts. Fibroblasts were transfected with the subtypes indicated and the peak current response to GABA or GABA plus furosemide was measured. The GABA concentration used was near the EC 50 value for each isoform. GABA or GABA plus furosemide was applied for 7-12 sec as indicated (bar) to cells voltageclamped at Ϫ50 mV. All traces shown are 50 sec in duration. The same time scale applies to all traces.
B, Concentration-response relationships were constructed by expressing the inhibition of the peak current by furosemide as a percentage of response to GABA alone for each cell. Symbols and bars, mean Ϯ standard error. Data for the ␣6␤3␥2L, ␣1/␣6␤3␥2L, and ␣6/␣1␤3␥2L isoforms were fit with a four-parameter logistic equation.
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GABA sites. Several amino acid residues in the large extracellular domain of many of the GABAR subunit families have been implicated in GABA binding (9, 20) . Therefore, it is not surprising that the primary determinant of the GABA EC 50 value for channel activity resided in the amino-terminal domain of the chimeric subtypes. The ␣1/␣6␤3␥2L isoform was closer in EC 50 value to the ␣1␤3␥2L isoform than to the ␣6␤3␥2L isoform, and the ␣6/␣1␤3␥2L isoform was closer in EC 50 value to the ␣6␤3␥2L isoform than to the ␣1␤3␥2L isoform. Interestingly, the EC 50 values for the chimeras were not equal or intermediate to the wild-type subtypes. Instead, the ␣6/␣1 chimera produced higher affinity for GABA than did the ␣6 subtype, whereas the ␣1/␣6 chimera conferred lower affinity than did the ␣1 subtype. This suggests that the amino-terminal domain alone does not determine the GABA EC 50 value. The remaining carboxyl-terminal domains of the ␣1 and/or ␣6 subtypes must also contribute to the ability of GABA to bind and/or activate the GABAR channel. The degree of shift in EC 50 value was nearly identical for both chimeric constructs, although they occurred in opposite directions. Therefore, it may be that the TM2-3 or carboxylterminal extracellular regions of the ␣1 subtype contribute to an increased sensitivity to GABA and/or that those of the ␣6 subtype reduce the sensitivity to GABA.
Direct activation by pentobarbital. Pentobarbital acts as an agonist at GABARs in addition to its action as a positive allosteric modulator of GABAR activity (21, 22) . Although the allosteric action is apparently independent of the subunit subtype composition of the receptor, direct activation is ␣ subtype dependent (7, 17) . At ␣6-containing receptors, pentobarbital is more efficacious than GABA, producing larger maximal currents. With ␣1-containing receptors, pentobarbital is as or slightly less efficacious than GABA, with a higher EC 50 value for activation than ␣6-containing receptors. Our results suggest that structural differences in the extracellular amino-terminal domain are responsible for the differences in pentobarbital activity. The ␣1/␣6 chimera had a response similar to the ␣1 subtype, whereas the ␣6/␣1 chimera was ␣6-like in both EC 50 value and efficacy compared with GABA. It has been shown that structures that alter GABA binding do not affect activation by pentobarbital (11) , but the functional properties of both of these agonists seem to be primarily determined by the same general domain, the extracellular amino terminus.
Diazepam site. Our results are consistent with the finding that H101 (in the rat ␣1 subtype), which is located in the amino-terminal extracellular domain, is required for diazepam sensitivity (8) . The ␣1/␣6 chimera conferred complete sensitivity to diazepam with an EC 50 value and maximum potentiation indistinguishable from those of the wild-type ␣1 subtype. The ␣6/␣1 chimera was completely insensitive to diazepam. This suggests that the amino-terminal extracellu- B, Concentration-response relationships were constructed by expressing the inhibition of the peak current by zinc as a percentage of response to GABA alone for each cell. Symbols and bars, mean Ϯ standard error. Data were fit with a fourparameter logistic equation. Downloaded from lar domain is principally responsible for the contribution of the ␣1 subtype to the functional domains for diazepam and that the remaining carboxyl-terminal domains do not contribute to the difference in diazepam sensitivity between the ␣1 and ␣6 subtypes.
Furosemide sites. Furosemide inhibits ␣6 subtype-containing receptors with high affinity, whereas ␣1 subtypecontaining receptors are almost 100-fold less sensitive. A high affinity site seemed to require the amino-terminal extracellular domain of the ␣6 subtype because the ␣6/␣1 chimera conferred the same sensitivity to furosemide as the wild-type ␣6 subtype. However, receptors containing the ␣1/␣6 chimera were also somewhat sensitive to furosemide, with an intermediate IC 50 value. This suggests that a second, lower affinity inhibitory site for furosemide was associated with the carboxyl-terminal domains of the ␣6 subtype. The appearance of the inhibited currents was also different for the two chimeras. The high affinity inhibition seen with the ␣6/␣1 chimera was uniform, with equal block of early and late currents. The lower affinity inhibition of the ␣1/␣6 chimera increased through the time of drug application, causing an increase in the degree of apparent desensitization. This is a common characteristic of open-channel blockers, which would be consistent with the involvement of the TMs in the formation of this inhibitory site. Although receptors containing the ␣6 subtype also showed this enhanced apparent desensitization, it appeared at lower concentrations of furosemide than required for receptors containing the ␣1/␣6 chimera. This could result from a positive interaction between the two proposed furosemide sites, resulting in an Fibroblasts were transfected with the subtypes indicated, and the peak current response to GABA or GABA plus lanthanum was measured. The GABA concentration used was near the EC 50 value for each isoform. GABA or GABA plus lanthanum was applied for 7-12 sec as indicated (bar) to cells voltage-clamped at Ϫ50 mV. All traces shown are 60 sec in duration. The same time scale applies to all traces. B, Concentration-response relationships were constructed by expressing the peak current in response to GABA plus lanthanum as a percentage of response to GABA alone for each cell. Symbols and bars, mean Ϯ standard error. Data for all isoforms except the ␣6/␣1␤3␥2L isoform were fit with a four-parameter logistic equation. (17) . This is similar to results seen with the ␣1/␣6 chimera (IC 50 ϭ 180 M) and suggests that the ␣4 subtype may contain the lower affinity site for furosemide but not the higher affinity site associated with the extracellular amino-terminal domain. Zinc site. The ␣6 subtype confers a greater sensitivity to zinc inhibition than the ␣1 subtype. This characteristic was associated with the carboxyl-terminal portion of the chimeras. Receptors containing the ␣1/␣6 chimera had ␣6 subtypelike affinity for zinc, whereas receptors containing the ␣6/␣1 chimera had ␣1 subtype-like affinity. This is in contrast to the findings with the 1 subtype of the GABA C receptor in which a histidine in the amino-terminal extracellular domain was responsible for zinc sensitivity (10) . The inhibition of GABAR currents by zinc is noncompetitive and voltage independent. The primary effect of zinc on single-channel kinetics is to reduce the frequency of channel opening rather than to reduce channel open time or conductance (23, 24) . This is consistent with zinc acting through an extracellular allosteric regulatory site rather than as a channel blocker. It has been suggested that the TM2-3 extracellular domain may be important in the regulation of zinc binding by the ␥ subunit (24) . The ␣6 subtype contains a histidine residue (H292) in this region, whereas the ␣1 subtype contains an asparagine residue (N301) in the equivalent location. Because histidine residues frequently contribute to zinc binding sites, this residue may play an important role in the zinc sensitivity of receptors containing the ␣6 subtype.
Lanthanum sites. Lanthanum affects the activity of ␣1 and ␣6 subtype-containing receptors in opposite directions, enhancing the activity of the ␣1␤3␥2L isoform while inhibiting the activity of the ␣6␤3␥2L isoform. The positive modulatory site seemed to be associated with the amino-terminal extracellular domain of the ␣1 subtype, with the ␣1/␣6 chimera conferring the same sensitivity and degree of enhancement as the ␣1 subtype. However, the ␣6/␣1␤3␥2L isoform showed an intermediate sensitivity, with only a slight enhancement by lanthanum. Neither receptor containing a chimera exhibited the inhibition seen with receptors containing the ␣6 subtype. The simplest explanation for this result is that structural domains from both regions of the ␣6 subtype are required for the formation of the inhibitory site.
Structure-function relationships of GABAR subunits. The structure of GABARs is complex, with five different subunits contributing to the functional properties of the receptor. We examined the structural domains responsible for contribution of the ␣1 and ␣6 subtypes to several allosteric regulatory sites of the GABAR. Whether the same or homologous structures form these sites for the other ␣ subtypes is not known. In addition, the ␣ subunit is clearly not solely responsible for the functional properties of these sites. The identity of the ␤ subtype also influences the response of the receptor to GABA, pentobarbital, and furosemide (4, 7, 19, 25) , and the ␥ subunit contributes to the functional properties of the GABA, diazepam, zinc, and lanthanum sites (5, 6, 18, 26, 27) . For the benzodiazepine site, a threonine residue (T142 in human ␥2) in the amino-terminal extracellular region of the ␥2 subtype has been found to be important for sensitivity (28) . This is in the same general domain as the histidine residue that confers benzodiazepine sensitivity in the ␣1 subtype. The regions of the ␤, ␥, and ␦ subunits that contribute to the functional properties of the other allosteric modulators are not necessarily structurally homologous to those for the ␣ subunit. To completely understand the structural properties of the regulatory sites of the GABAR, the contributions that the other subunits make to these sites must also be examined.
